Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1765P - The lack of KRAS variation and its therapeutic implication in MSI-H colorectal cancer with NTRK fusion

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Translational Research

Tumour Site

Presenters

Chenlu Zhang

Citation

Annals of Oncology (2021) 32 (suppl_5): S1211-S1226. 10.1016/annonc/annonc716

Authors

C. Zhang1, X. Guo1, Y. You1, Z. Wang1, R. Zhuang1, F. Zhao2, H. Chen3, S. Chen3, Y. Bai3, X. Zhao3

Author affiliations

  • 1 Oncology Department, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 2 Medical Affairs, 3D Medicines Inc. - Headquarter, 201114 - Shanghai/CN
  • 3 The Medical Department, 3D Medicines Inc., 201114 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1765P

Background

The prevalence of NTRK fusion in colorectal cancer (CRC) was very low (about 0.35%), and a majority of them happened in MSI-H CRC. As MSI-H was a well-known predictor of immune-checkpoint inhibitor (ICI) therapy, whether NTRK fusion has synergistic or antagonistic effect on MSI-H was unknown.

Methods

Tumor tissue and paired white blood cells from more than 20000 patients with solid tumor were collected and somatic variation and MSI status were analyzed by 74 cancer-related genes and 500 MSI loci in a CLIA-certified laboratory (3Medicine Inc.).

Results

Totally, 46 patients harbored one or more NTRK fusions, including 14 CRCs, 15 lung cancers, and 17 other cancer-types. In NTRK fusion-positive CRC patients, 78.57% (11/14) were MSI-H. Importantly, none of MSI-H CRC patients with NTRK fusion harbored KRAS variation. However, among 299 MSI-H CRC patients without NTRK fusion, 50.17% (150/299) harbored KRAS variation, which was significantly higher than the former (adjusted p-value = 0.03). KRAS variation was known as a negative predictor of ICI therapy in MSI-H CRC, which suggested that MSI-H patients with NTRK fusion may be more likely to benefit from ICI therapy. Besides KRAS, NRAS and TSC2 variations were also undetected in the NTRK fusion-positive and MSI-H CRC patients, and the frequency of TSC2 variation was higher in MSI-H patients without NTRK fusion (p-value = 0.04). Furthermore, in NTRK fusion-positive lung cancers (LC), the most frequently mutated genes were TP53 and EGFR, similar to that in LC without NTRK fusion. And no gene having significantly different variation frequency between NTRK fusion-positive and -negative LC was detected. In NTRK fusion-positive patients of various cancer types other than CRC and LC, the only frequently mutated gene was TP53. However, key driver genes like EGFR, PIK3CA, ROS1, APC, and CTNNB1 were detected in a few patients. Together, the previous report that NTRK fusion-positive patients were generally lack of driver gene variation may be inaccurate.

Conclusions

NTRK fusion and KRAS variation may be mutually exclusive in MSI-H CRC. And MSI-H CRC with NTRK fusion-positive patients may be more likely to benefit from ICI therapy, which worth further validating in clinical trial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.